Trial reportPloS one2025
Effects of a polypill on circulating levels of resistin and visfatin in men with non-alcoholic fatty liver disease: A five-year clinical trial.
Trial report in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease globally, characterized by insulin resistance, hypertension, and obesity. Adipokines such as resistin and visfatin play significant roles in glucose homeostasis and lipid metabolism. Polypills are utilized to improve cardiovascular disease (CVD) risk factors. The present observational study was nested within the PolyIran-Liver randomized controlled trial, which primarily assessed clinical outcomes in NAFLD patients. This study aimed to evaluate the effects of prolonged polypill consumption (five years) on circulating levels of resistin and visfatin as secondary outcomes in men with NAFLD. Participants from the PolyIran-Liver trial were included, comprising 41 patients in the control group and 40 patients in the polypill group, all of whom were men. The polypill regimen included aspirin, hydrochlorothiazide, atorvastatin, and valsartan. Treatment with the polypill resulted in a significant reduction in visfatin levels (2.27 ± 0.83 ng/ml vs. 2.10 ± 0.71 ng/ml, AdjP = 0.041), but no significant changes in resistin levels were observed within the polypill group (19.54 ± 4.11 ng/ml vs. 19.11 ± 3.08 ng/ml, AdjP = 0.396). The reduction in visfatin levels from baseline was significantly associated with changes in resistin levels and fasting blood glucose (FBG) (P < 0.05). Additionally, polypill intervention improved alanine aminotransferase (ALT) levels, lipid profiles, and systolic blood pressure in patients with NAFLD (P < 0.05). Our findings suggest that daily intake of the polypill can lead to significant reductions in visfatin levels and improvements in metabolic parameters in men with NAFLD. Further studies are needed to evaluate the long-term implications of polypill consumption in managing NAFLD through targeting adipokines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.